Guggenheim Defending Dianthus Therapeutics (DNTH): 'We reiterate our positive view'

June 10, 2026 4:10 PM

Guggenheim analyst Yatin Suneja reiterated a Buy rating and $200.00 price target on Dianthus Therapeutics (NASDAQ: DNTH)The analyst comments "Sanofi ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found